6-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptan-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)-N,2-dimethyl-benzofuran-3-carboxamide | 1210828-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptan-5-yl)propoxy)-6-methoxyquinolin-4-yloxy)-N,2-dimethyl-benzofuran-3-carboxamide
• 英文别名: 6-[7-[3-(7-hydroxy-5-azaspiro[2.4]heptan-5-yl)propoxy]-6-methoxyquinolin-4-yl]oxy-N,2-dimethyl-1-benzofuran-3-carboxamide
• CAS: 1210828-27-5
• 化学式: C₃₀H₃₃N₃O₆
• 分子量: 531.609
• InChiKey: AHHVDMLPZJPQSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Compounds As Kinase Inhibitors
  申请人：CHEN GUOQING PAUL

  公开号：US20100048599A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.

  本发明涉及公式I的化合物，其制备方法，含有其作为活性成分的药物组合物，用于治疗与血管生成有关的疾病状态的方法，如与蛋白酪氨酸激酶相关的癌症，以及它们作为药物在生产中用于减少温血动物（如人类）中酪氨酸激酶的抑制效果。
• COMPOUNDS AS KINASE INHIBITORS
  申请人：Advenchen Laboratories, LLC

  公开号：EP2312950B1

  公开（公告）日：2016-11-30
• JP2012500269A
  申请人：——

  公开号：JP2012500269A

  公开（公告）日：2012-01-05
• US8211911B2
  申请人：——

  公开号：US8211911B2

  公开（公告）日：2012-07-03
• [EN] COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE KINASES
  申请人：ADVENCHEN LAB LLC

  公开号：WO2010021918A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.